Open this publication in new window or tab >>Show others...
2025 (English)In: Drug Design, Development and Therapy, E-ISSN 1177-8881, Vol. 19, p. 4039-4091Article, review/survey (Refereed) Published
Abstract [en]
Pyridine carboxylic acid isomers - picolinic acid, nicotinic acid, and isonicotinic acid - have historically resulted in a plethora of drugs against tuberculosis, cancer, diabetes, Alzheimer's, angina, dementia, depression, allergy, respiratory acidosis, psoriasis, acne, hypertension, hyperlipidemia, HIV/AIDS (specifically HIV-1), among others. Despite the large number of therapeutic agents derived from these isomers, the research involving these scaffolds is still exceptionally active. The current surge in enzyme inhibitory activities by the compounds derived from them has further created space for the discovery of new drug candidates. This review focuses on the medicinal relevance of these isomers by analyzing structure-activity relationships (SARs) and highlighting emerging trends from patents filed over the last decade. Notably, pharmaceutical giants like Bayer, Bristol-Myers Squibb, Novartis, Curis, and Aurigene have developed enzyme inhibitors based on these scaffolds with nanomolar potency. The role of these isomers in the development of antiviral agents, including protease inhibitors, is also discussed. Overall, this review brings to the readers, a pragmatic opportunity to comprehend the recent literature, highlighting the scaffolds' importance in the design of new enzyme inhibitors. Furthermore, it discusses the structure-activity relationship of pyridine carboxylic acid-derived compounds and highlights the current patenting trends in medicinal chemistry.
Place, publisher, year, edition, pages
Dove Medical Press, 2025
Keywords
pyridine, enzyme inhibitors, nitrogen heterocycles, patents, pharmaceuticals, current trend, substituent effect
National Category
Pharmaceutical Sciences Medicinal Chemistry
Identifiers
urn:nbn:se:uu:diva-559938 (URN)10.2147/DDDT.S513461 (DOI)001503916200001 ()40420948 (PubMedID)2-s2.0-105006844547 (Scopus ID)
2025-06-172025-06-172025-06-17Bibliographically approved